Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 17 Aug 2022
COVID vaccine rollout too slow, poorly planned, audit finds
17 August 2022 - An audit of Australia’s coronavirus vaccination rollout has criticised the slow speed at which early doses ...
Posted by Michael Wonder on 17 Aug 2022
Akorn announces FDA has approved generic cetrorelix acetate
16 August 2022 - Akorn announces that it received FDA approval for a generic version of cetrorelix acetate 250 mcg ...
Posted by Michael Wonder on 17 Aug 2022
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
17 February 2022 - Regulatory submission included data from the pivotal MOMENTUM Phase 3 clinical trial that met all primary ...
Posted by Michael Wonder on 17 Aug 2022
UK will not buy Evusheld owing to “insufficient data” on protection, Government says
15 August 2022 - The UK Government has said that it will not procure the COVID-19 drug Evusheld—a combination of ...
Posted by Michael Wonder on 17 Aug 2022
PHARMAC estimates Trikafta could give people with CF another 27 years
17 August 2022 - PHARMAC has today published the record of advice from the May PTAC meeting to again consider ...
Posted by Michael Wonder on 17 Aug 2022
Restart of the National Medicines Policy review – further consultation on a revised draft
17 August 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised ...
Posted by Michael Wonder on 16 Aug 2022
Sales from controversial drug discount program rose to $44 billion last year
15 August 2022 - Prescription medicines purchased in the US under a controversial government discount program amounted to $44 billion ...
Posted by Michael Wonder on 16 Aug 2022
Cancer patient who devoted six years to drug pricing reform isn’t done yet
14 August 2022 - After six years of relentless advocacy work, David Mitchell was finally on the cusp of defeating ...
Posted by Michael Wonder on 16 Aug 2022
Unpacking the drug pricing policies that Congress just approved
16 August 2022 - Medicare coverage for prescription drugs will look very different when President Biden signs into law the ...
Posted by Michael Wonder on 16 Aug 2022
Otsuka Canada Pharmaceutical announces Health Canada approval of Korsuva (difelikefalin) for the treatment of moderate to severe pruritus associated with chronic kidney disease in adult haemodialysis patients
16 August 2022 - Launch of Korsuva in Canada is expected in the second quarter of 2023. ...
Posted by Michael Wonder on 16 Aug 2022
EMA publishes agenda for 16-19 August CHMP meeting
16 August 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 16 Aug 2022
Chugai obtains regulatory approval for osteoporosis treatment Edirol
15 August 2022 - Chugai Pharmaceutical and Towa Pharmaceutical announced that Chugai obtained regulatory approval from the MHLW for an ...
Posted by Michael Wonder on 16 Aug 2022
Kidney patients cite insurance and payment issues as critical barriers to FDA approved care innovations
15 August 2022 - Patients and taxpayers forced to absorb preventable costs. ...
Posted by Michael Wonder on 16 Aug 2022
Visibly becomes first FDA cleared online vision test in the United States
16 August 2022 - Visibly is excited to announce that, as of 12 August 2022, it has received 510(k) clearance ...
Posted by Michael Wonder on 16 Aug 2022
GPs demand action to fix ‘disintegrating’ Medicare
17 August 2022 - Doctors have issued the federal government with an urgent demand for more Medicare funding, warning general ...